Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04311476Phase 2Completed

Autologous Cord Blood Cells for Prevention of BPD in Preterm

Role: lead

NCT04348799Completed

Thrombocytopoiesis and Platelet Homeostasis in Infants With Bronchoplumonary Dysplasia

Role: lead

NCT03855202Phase 1Unknown

The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms

Role: lead

NCT03104946Completed

To Research the Relation Between Neonatal Morbidities and Poor Outcome in Preterm Infants

Role: lead

All 4 trials loaded